03:40 PM
Monday January 17 2022
I wrote – Shaima Hefzy:
Tenth of Ramadan Pharmaceutical Industries – Rameda said in a statement to the Stock Exchange today, Monday, that it will start the production of the “Molnopiravir Rameda” antiviral drug approved to treat the Covid-19 virus.
Rameda said that it is coordinating its production plans with the Egyptian Medicines Authority and the Ministry of Health to ensure that the market needs of this drug are fully met in a timely manner, according to the statement.
The company explained that the treatment, which will begin production, will be developed by the American company Merck, and it is an oral treatment.
Rameda intends to release the first batch of Molnupiravir Rameda before the end of the first quarter of this year at a price of 625 pounds for a package that contains 40 capsules at a concentration of 200 mg.
She said that this concentration is approved by the US Food and Drug Administration and the Medicines and Health Care Products Regulatory Agency in Britain.
And it was allowed to produce Merck, following it was approved by the US Food and Drug Administration for emergency use, and licensed by the Medicines and Healthcare products Regulatory Agency in Britain, to treat mild and moderate infections of the Corona virus in adults at high risk of developing severe infection.
Earlier this month, the Egyptian International Pharmaceutical Industries Company, EPICO, announced the start of manufacturing Merck’s drug in Egypt.
Rameda said that it is coordinating its production plans with the Egyptian Medicines Authority and the Ministry of Health to ensure that the market needs of this drug are fully met in a timely manner, according to the statement.
.
